HRP20150956T1 - Polimorfni oblik rotigotina - Google Patents
Polimorfni oblik rotigotina Download PDFInfo
- Publication number
- HRP20150956T1 HRP20150956T1 HRP20150956TT HRP20150956T HRP20150956T1 HR P20150956 T1 HRP20150956 T1 HR P20150956T1 HR P20150956T T HRP20150956T T HR P20150956TT HR P20150956 T HRP20150956 T HR P20150956T HR P20150956 T1 HRP20150956 T1 HR P20150956T1
- Authority
- HR
- Croatia
- Prior art keywords
- rotigotine
- polymorphic form
- medicinal substance
- parkinson
- pharmaceutical composition
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims 20
- 229960003179 rotigotine Drugs 0.000 title claims 20
- 239000012907 medicinal substance Substances 0.000 claims 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229960003638 dopamine Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 238000002083 X-ray spectrum Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Polimorfni oblik (II) Rotigotina ((-)-5,6,7,8-tetrahidro-6-[propil[2-(2-tienil)etil]-amino]-1-nafthalenol) koji ima najmanje jedno od:
Rendgenski spektar praha koji sadrži pikove pri slijedećim ° 2θ uglovima (± 0.2): 12.04, 13.68, 17.72 i 19.01, mjereno Cu-Kα zračenjem (1.54060 Å);
Raman spektar koji sadrži pikove pri sljedećim valnim brojevima (± 3 cm-1) odabranim od: 226.2, 297.0, 363.9, 710.0, 737.3, 743.3, 750.8, 847.3, 878.3, 1018.7, 1075.6, 1086.2, 1214.3, 1255.1, 1278.2, 1330.7, 1354.3 i 1448.7;
DSC pik sa Tonset na 97°C ± 2°C mjereno pri brzini zagrijavanja od 10 °/min;
točku taljenja na 97°C ± 2°C.
2. Polimorfni oblik Rotigotina koji ima rendgenski spektar difrakcije praha mjeren Cu-Kα zračenjem (1.54060 Å) supstancijalno kao prikazano na Slici 1.
3. Rotigotin ljekovita supstanca koja sadrži najmanje 5% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
4. Rotigotin ljekovita supstanca koja sadrži najmanje 50% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
5. Rotigotin ljekovita supstanca koja sadrži najmanje 90% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
6. Rotigotin ljekovita supstanca koja sadrži najmanje 95% polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2.
7. Rotigotin ljekovita supstanca prema bilo kojem od patentnih zahtjeva 3-6 za upotrebu kao terapeutski aktivna supstanca.
8. Kristalni polimorf prema bilo kojem od patentnih zahtjeva 1 do 2 za upotrebu kao terapeutski aktivna supstanca.
9. Upotreba polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2 ili Rotigotin ljekovite supstance prema patentnim zahtjevima 3-6 i najmanje jednog farmaceutski prihvatljivog ekscipijensa u postupku proizvodnje farmaceutskog sastava.
10. Upotreba prema patentnom zahtjevu 9, naznačena time što je farmaceutski sastav u obliku transdermalnog terapeutskog sustava.
11. Metoda za proizvodnju farmaceutskog sastava korištenjem polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2 ili Rotigotin ljekovite supstance prema zahtjevima 3-6 i najmanje jednog farmaceutski prihvatljivog ekscipijensa.
12. Metoda prema zahtjevu 11, naznačena time da je farmaceutski sastav u obliku transdermalnog terapeutskog sustava.
13. Polimorfni oblik Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2 ili Rotigotin ljekovita supstanca prema zahtjevima 3-6 za upotrebu u postupku liječenja pacijenta koji pati od poremećaja povezanih sa dopaminom, gdje je spomenuti poremećaj odabran od Parkinsonove Bolesti Parkinsonovog plus sindroma, depresije, fibromijalgije i/ili sindroma nemirnih nogu.
14. Upotreba polimorfnog oblika Rotigotina kako je definirano u bilo kojem od patentnih zahtjeva 1-2 ili Rotigotin ljekovite supstance prema patentnim zahtjevima 3-6 za proizvodnju lijeka za liječenje pacijenta koji pati od poremećaja povezanih sa dopaminom, gdje je sa dopaminom povezani poremećaj odabran od Parkinsonove bolesti, Parkinsonovog plus sindroma, depresije, fibromijalgije i/ili sindroma nemirnih nogu.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99072107P | 2007-11-28 | 2007-11-28 | |
EP07121795 | 2007-11-28 | ||
EP08166576 | 2008-10-14 | ||
PCT/EP2008/066137 WO2009068520A2 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
EP08853236.1A EP2215072B1 (en) | 2007-11-28 | 2008-11-25 | Polymorphic form of rotigotine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20150956T1 true HRP20150956T1 (hr) | 2016-01-15 |
Family
ID=40676399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150956TT HRP20150956T1 (hr) | 2007-11-28 | 2015-09-10 | Polimorfni oblik rotigotina |
Country Status (28)
Country | Link |
---|---|
US (2) | US8592477B2 (hr) |
EP (1) | EP2215072B1 (hr) |
JP (1) | JP5391204B2 (hr) |
KR (1) | KR101694551B1 (hr) |
CN (1) | CN101970422B (hr) |
AR (1) | AR070036A1 (hr) |
AU (1) | AU2008328920B2 (hr) |
CA (1) | CA2703561C (hr) |
DK (1) | DK2215072T3 (hr) |
EA (1) | EA017836B1 (hr) |
ES (1) | ES2547231T3 (hr) |
HK (1) | HK1143162A1 (hr) |
HR (1) | HRP20150956T1 (hr) |
HU (1) | HUE027647T2 (hr) |
IL (1) | IL204991A (hr) |
ME (1) | ME02275B (hr) |
MX (1) | MX2010005925A (hr) |
MY (1) | MY165575A (hr) |
NZ (1) | NZ584363A (hr) |
PH (1) | PH12013501503A1 (hr) |
PL (1) | PL2215072T3 (hr) |
PT (1) | PT2215072E (hr) |
RS (1) | RS54235B1 (hr) |
SG (1) | SG10201610626PA (hr) |
SI (1) | SI2215072T1 (hr) |
TW (1) | TWI418349B (hr) |
WO (1) | WO2009068520A2 (hr) |
ZA (1) | ZA201002192B (hr) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
DE10234673B4 (de) | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
PL1750766T3 (pl) | 2004-05-11 | 2013-12-31 | Eb Ip Lybrido B V | Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
US8344165B2 (en) | 2007-05-30 | 2013-01-01 | Chemagis Ltd. | Crystalline rotigotine base and preparation process therefor |
NZ584363A (en) | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
DE102009052972A1 (de) | 2009-11-12 | 2011-09-15 | Lts Lohmann Therapie-Systeme Ag | Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm |
EP3257504B1 (en) | 2009-12-22 | 2024-06-19 | UCB Biopharma SRL | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2012084969A1 (en) | 2010-12-22 | 2012-06-28 | Hexal Ag | Adhesive composition containing rotigotine and transdermal therapeutic system comprising the adhesive composition |
EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014136122A1 (en) * | 2013-03-04 | 2014-09-12 | Mylan Laboratories Limited | Process for the preparation of rotigotine polymorphic form-i |
BR112015032929B1 (pt) | 2013-07-03 | 2022-08-23 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico |
ES2924899T3 (es) | 2014-05-20 | 2022-10-11 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que contiene rotigotina |
ES2954087T3 (es) | 2014-05-20 | 2023-11-20 | Lts Lohmann Therapie Systeme Ag | Sistema de administración transdérmica que incluye un mediador de interfase |
CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
WO2015186138A1 (en) * | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
EP3730129A4 (en) | 2017-12-19 | 2020-12-09 | Hisamitsu Pharmaceutical Co., Inc. | ROTIGOTINE PLASTER |
KR20210104101A (ko) | 2019-02-15 | 2021-08-24 | 히사미쓰 세이야꾸 가부시키가이샤 | 로티고틴 안정화 방법 |
PL3854388T3 (pl) | 2020-01-24 | 2024-02-26 | Luye Pharma Switzerland Ag | Transdermalny system terapeutyczny z substancją czynną rotygotyną i co najmniej jednym klejem silikonowym nieodpornym na działanie amin |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4320148A (en) * | 1980-11-24 | 1982-03-16 | Smithkline Corporation | 2-Aminotetralin compounds, pharmaceutical compositions and method of producing central alpha1 agonist activity |
US5177112A (en) * | 1983-01-03 | 1993-01-05 | Whitby Research, Inc. | Substituted 2-aminotetralins |
US4540691A (en) | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
US4885308A (en) | 1984-08-13 | 1989-12-05 | Nelson Research & Development Co. | Method and compositions for treatment of parkinsonism syndrome in mammals |
US5214156A (en) | 1988-03-25 | 1993-05-25 | The Upjohn Company | Therapeutically useful tetralin derivatives |
US5545755A (en) | 1989-05-31 | 1996-08-13 | The Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
HUT61719A (en) * | 1989-05-31 | 1993-03-01 | Upjohn Co | Process for producing 2-aminotetraline derivatives and pharmaceutical compositions comprising such compounds |
US5486611A (en) | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
US5151446A (en) | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
EP0591426A4 (en) | 1991-06-27 | 1996-08-21 | Univ Virginia Commonwealth | Sigma receptor ligands and the use thereof |
SE9301732D0 (sv) | 1993-05-18 | 1993-05-18 | Haakan Wilhelm Wikstroem | New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins |
US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE19814083C2 (de) | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
EP1232152B1 (en) * | 1999-11-23 | 2004-02-04 | Aderis Pharmaceuticals, Inc. | Improved process for preparing nitrogen-substituted aminotetralins |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
DE60100595T2 (de) | 2001-05-08 | 2004-06-24 | Lts Lohmann Therapie-Systeme Ag | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
FR2828212B1 (fr) | 2001-08-03 | 2003-10-31 | Aventis Pharma Sa | Methodes de diagnostic et de pronostic de la maladie de parkinson |
FR2829028B1 (fr) * | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
MXPA04009352A (es) * | 2002-04-18 | 2005-01-25 | Pharmacia Corp | Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2). |
DE10220230A1 (de) | 2002-05-06 | 2003-11-27 | Sanol Arznei Schwarz Gmbh | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
US20040048779A1 (en) | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
US20060216336A1 (en) * | 2002-05-07 | 2006-09-28 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8246979B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
US7038085B2 (en) | 2002-10-25 | 2006-05-02 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
ES2239196T3 (es) | 2002-12-02 | 2005-09-16 | Schwarz Pharma Ag | Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson. |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US7348762B2 (en) | 2003-05-01 | 2008-03-25 | Sony Corporation | Battery pack and method for producing battery pack |
DE10334188B4 (de) | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10334187A1 (de) | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
US20050197385A1 (en) | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
US8344165B2 (en) | 2007-05-30 | 2013-01-01 | Chemagis Ltd. | Crystalline rotigotine base and preparation process therefor |
WO2009063170A1 (en) | 2007-11-16 | 2009-05-22 | Pliva Hrvatska D.O.O. | Preparation of crystalline rotigotine base |
NZ584363A (en) | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
EP2281559A1 (en) * | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
EP3257504B1 (en) | 2009-12-22 | 2024-06-19 | UCB Biopharma SRL | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2015186138A1 (en) | 2014-06-03 | 2015-12-10 | Davaluri Ramamohan Rao | Improved process for the preparation of crystalline form ii of rotigotine |
-
2008
- 2008-11-25 NZ NZ584363A patent/NZ584363A/xx unknown
- 2008-11-25 AU AU2008328920A patent/AU2008328920B2/en active Active
- 2008-11-25 HU HUE08853236A patent/HUE027647T2/en unknown
- 2008-11-25 MX MX2010005925A patent/MX2010005925A/es active IP Right Grant
- 2008-11-25 ME MEP-2015-136A patent/ME02275B/me unknown
- 2008-11-25 JP JP2010535352A patent/JP5391204B2/ja active Active
- 2008-11-25 MY MYPI2010001680A patent/MY165575A/en unknown
- 2008-11-25 RS RS20150578A patent/RS54235B1/en unknown
- 2008-11-25 EP EP08853236.1A patent/EP2215072B1/en not_active Revoked
- 2008-11-25 WO PCT/EP2008/066137 patent/WO2009068520A2/en active Application Filing
- 2008-11-25 ES ES08853236.1T patent/ES2547231T3/es active Active
- 2008-11-25 CA CA2703561A patent/CA2703561C/en active Active
- 2008-11-25 SG SG10201610626PA patent/SG10201610626PA/en unknown
- 2008-11-25 PL PL08853236T patent/PL2215072T3/pl unknown
- 2008-11-25 KR KR1020107010562A patent/KR101694551B1/ko active IP Right Review Request
- 2008-11-25 DK DK08853236.1T patent/DK2215072T3/en active
- 2008-11-25 SI SI200831499T patent/SI2215072T1/sl unknown
- 2008-11-25 EA EA201000384A patent/EA017836B1/ru not_active IP Right Cessation
- 2008-11-25 CN CN200880110877.9A patent/CN101970422B/zh active Active
- 2008-11-25 US US12/744,989 patent/US8592477B2/en active Active
- 2008-11-25 PT PT88532361T patent/PT2215072E/pt unknown
- 2008-11-26 TW TW097145595A patent/TWI418349B/zh active
- 2008-11-26 US US12/324,166 patent/US8232414B2/en active Active
- 2008-11-28 AR ARP080105189A patent/AR070036A1/es unknown
-
2010
- 2010-03-29 ZA ZA2010/02192A patent/ZA201002192B/en unknown
- 2010-04-11 IL IL204991A patent/IL204991A/en active IP Right Grant
- 2010-10-14 HK HK10109729.7A patent/HK1143162A1/xx unknown
-
2013
- 2013-07-15 PH PH12013501503A patent/PH12013501503A1/en unknown
-
2015
- 2015-09-10 HR HRP20150956TT patent/HRP20150956T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150956T1 (hr) | Polimorfni oblik rotigotina | |
Subedi et al. | An overview of tramadol and its usage in pain management and future perspective | |
HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
JP2011516417A5 (hr) | ||
JP2007500154A5 (hr) | ||
JP2009520690A5 (hr) | ||
HRP20161291T1 (hr) | Soli fenotiazin-diamina i njihova uporaba | |
NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
JP2013237682A5 (hr) | ||
JP2011527333A5 (hr) | ||
CN101534809A (zh) | 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途 | |
HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
HRP20151334T1 (hr) | Derivat kateholamina koristan u lijeäśenju parkinsonove bolesti | |
JP2010535252A5 (hr) | ||
JP2011504490A5 (hr) | ||
HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
CN101955440B (zh) | 一种阿戈美拉汀新晶型及其制备方法 | |
AR075625A1 (es) | Tratamiento de trastornos relacionados con la discinesia | |
NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
JP2021505575A5 (hr) | ||
JP2013541583A5 (hr) | ||
JP2015514797A5 (hr) | ||
RU2014145931A (ru) | Композиция для лечения нарушений метаболизма | |
MX2011008627A (es) | Metodos de administracion de (4ar, 10ar)-1-n-propil-1,2,3,4,4a,5,1 0,10a-octahidro-benzo[g]quinolin-6,7-diol y compuestos relacionados a traves de la mucosa oral, la mucosa nasal o la piel y composiciones farmaceuticas de los mismos. |